Citius Pharmaceuticals, Inc. (CTXR) intrinsic value & 10-year financials
Citius Pharmaceuticals, Inc. (CTXR) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.46
- Market cap
- $5.1M
- Revenue (FY2025)
- —
- Revenue growth (10-yr CAGR)
- 12.5%
- ROIC (10-yr avg)
- -54.9%
- Free cash flow (FY2025)
- —
CTXR 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$39.7M | -$3.38 | — | — | -17.9% |
| FY2024 | — | -$39.4M | -$5.97 | — | — | -63.9% |
| FY2023 | — | -$32.5M | -$5.57 | — | — | -58.2% |
| FY2022 | $90.0K | -$33.6M | -$0.23 | — | -37017.8% | -53.6% |
| FY2021 | $90.0K | -$23.1M | -$0.23 | -$24.3M | -26146.5% | -56.4% |
| FY2020 | $90.0K | -$17.5M | — | -$16.9M | -19678.5% | -85.7% |
| FY2019 | $90.0K | -$15.6M | — | — | -17331.5% | -59.6% |
| FY2018 | $75.0K | -$12.5M | — | — | -18385.5% | -50.3% |
| FY2017 | $50.0K | -$10.4M | — | -$8.0M | -19972.6% | -53.6% |
| FY2016 | — | -$8.3M | — | — | — | -49.5% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Citius Pharmaceuticals, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Citius Pharmaceuticals, Inc. has historically struggled to out-earn its cost of capital, averaging just -54.9% ROIC.
Citius Pharmaceuticals, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Citius Pharmaceuticals, Inc. is modeled at 12.5% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-97.51 per share.